Maintenance oral viscous budesonide reduces dilation recurrence after esophageal atresia repair: a prospective clinical study - Quiz - MDSpire

Maintenance oral viscous budesonide reduces dilation recurrence after esophageal atresia repair: a prospective clinical study

  • By

  • Cosimo Ruggiero

  • Giusy Russo

  • Denis Cozzi

  • Danila Volpe

  • Silvia Ceccanti

  • Paola Papoff

  • Miriam D’Orsi

  • Tonia Raso

  • Giulia Mancuso

  • Salvatore Oliva

  • May 14, 2026

  • 0 min

Share

Original Source(s)

Maintenance oral viscous budesonide reduces dilation recurrence after esophageal atresia repair: a prospective clinical study

  • by Cosimo Ruggiero, Giusy Russo, Denis Cozzi, Danila Volpe, Silvia Ceccanti, Paola Papoff, Miriam D’Orsi, Tonia Raso, Giulia Mancuso, Salvatore Oliva

  • May 14, 2026

Related Content

NLRP3 inflammasomes at the ARDS-cancer interface: mechanisms and translational hypotheses

Case Report and retrospective literature analysis of pediatric lower esophageal squamous cell carcinoma: focus on diagnostic challenges and therapeutic strategies

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.